Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "PsA"

New Data Highlight Effectiveness of Guselkumab for Patients with PsA

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2022

The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.

FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2022

The FDA has approved the use of secukinumab for pediatric patients with enthesitis-related arthritis and psoriatic arthritis, after research showed a longer time to disease flare than placebo.

Risk of IBD in Patients with Psoriasis, PsA & Ankylosing Spondylitis Starting IL-17 Inhibitors

Arthritis & Rheumatology  |  February 2, 2022

In February A&R, Penso et al. reported on the results of their study, which explored whether patients with psoriasis, PsA and AS have a higher risk of developing IBD when treated with an IL-17 inhibitor compared with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, or etanercept, a TNF inhibitor.

Risankizumab Effective Against Refractory Psoriatic Arthritis

Matthew Phelan  |  January 22, 2022

NEW YORK (Reuters Health)—Risankizumab, an inhibitor of interleukin (IL) 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial. “Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse…

The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice

Mary Beth Nierengarten  |  December 2, 2021

Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.

Oral CBD Fails to Relieve Pain from Hand OA & PsA

Reuters Staff  |  September 21, 2021

NEW YORK (Reuters Health)—Lower doses of cannabidiol (CBD) failed to provide any meaningful reduction in pain when added to other analgesic therapy in patients with hand osteoarthritis (OA) or psoriatic arthritis (PsA) in a randomized, placebo-controlled study from Denmark.1 Writing in the journal, Pain, Jonathan Vela, MD, and colleagues of Aalborg University note that CBD…

EU Approves Tofacitinib Citrate for 2 Pediatric Conditions

Michele B. Kaufman, PharmD, BCGP  |  September 8, 2021

The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.

Health Canada Approves Upadacitinib to Treat Adults with PsA

Michele B. Kaufman, PharmD, BCGP  |  July 6, 2021

Based on data from two phase 3 clinical trials, Health Canada has approved the use of upadacitinib to treat adults with active psoriatic arthritis.

Risankizumab May Improve Symptoms of PsA

Michele B. Kaufman, PharmD, BCGP  |  January 21, 2021

Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.

Apremilast Most Helpful for Mild to Moderate Psoriatic Arthritis

Lara C. Pullen, PhD  |  May 18, 2020

Recent research examined the use of apremilast in patients with psoriatic arthritis using the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) measurement. The findings suggest patients with moderate disease activity at baseline benefit most from the treatment…

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences